The Vanguard Group, Inc. recently announced the acquisition of new stake in Ekso Bionics Holdings Inc. (NASDAQ:EKSO). The institutional investor has increased its shareholding in the Healthcare company by 0.02% to 0.44 million shares with purchase of 100.0 shares. This fresh investment now brings its stake to 3.32% valued currently at $0.45 million. In addition, Essex Investment Management Co. L raised its holdings by 0.15 million to 0.32 million shares. And Renaissance Technologies LLC has lifted its position by 6.28% or 2800.0 shares – to 47406.0 shares.
With over 0.39 million Ekso Bionics Holdings Inc. (EKSO) shares trading Tuesday and a closing price of $1.60 on the day, the dollar volume was approximately $0.62 million. The shares have shown a negative half year performance of -6.15% and its price on 01/10/23 gained nearly 18.87%. Currently, there are 13.07M common shares owned by the public and among those 12.07M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for EKSO have a consensus price objective of $9.00. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $9.00. The average price target is 82.22% above its recent price level and an upside to the estimated low will see the stock gain 82.22% over that period. But an upside of 82.22% will see the stock hit the forecast high price target while median target price for the stock is $9.00.
Insiders at the company have transacted a total of 47 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 26 of these insider trades were purchases, accounting for 1,314,057 shares. Insider sales of the common stock occurred on 21 occasions, with total insider shares sold totaling 102,533 shares.
The top 3 mutual fund holders in Ekso Bionics Holdings Inc. are AZ Fund 1 – AZ Allocation – Trend, Vanguard Total Stock Market Index, and Vanguard Extended Market Index Fu. AZ Fund 1 – AZ Allocation – Trend owns 0.6 million shares of the company’s stock, all valued at over $0.62 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.36% of the shares outstanding.
Shares of Ekso Bionics Holdings Inc. (NASDAQ: EKSO) opened at $1.34, down -$0.01 from a prior closing price of $1.35. However, the script later moved the day high at 1.6500, up 18.87%. The company’s stock has a 5-day price change of 21.58% and 2.88% over the past three months. EKSO shares are trading 34.87% year to date (YTD), with the 12-month market performance down to -39.89% lower. It has a 12-month low price of $1.03 and touched a high of $3.15 over the same period. EKSO has an average intraday trading volume of 44.50K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 21.90%, 19.81%, and -12.89% respectively.
Institutional ownership of Ekso Bionics Holdings Inc. (NASDAQ: EKSO) shares accounts for 16.50% of the company’s 13.07M shares outstanding. Mutual fund holders own 6.86%, while other institutional holders and individual stakeholders account for 9.50% and 14.86% respectively.
It has a market capitalization of $21.28M and a beta (3y monthly) value of 1.58. The earnings-per-share (ttm) stands at -$1.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.97% over the week and 8.61% over the month.
Analysts forecast that Ekso Bionics Holdings Inc. (EKSO) will achieve an EPS of -$0.24 for the current quarter, -$0.22 for the next quarter and -$0.54 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.15 a year ago. Earnings per share for the fiscal year are expected to increase by 59.90%, and 48.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Ekso Bionics Holdings Inc. (EKSO) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”